Related Experiment Video
Updated: Jun 8, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Estimation of an optimal chemotherapy utilisation rate for primary malignant brain tumours: an evidence-based
1University of New South Wales and Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital, Liverpool, New South Wales, Australia. Susannah.Jacob@sswahs.nsw.gov.au
Aims:
The optimal chemotherapy utilisation rate can serve as a benchmark to assess the quality of cancer care. The aim of this study was to determine the optimal proportion of patients with primary malignant brain tumours for whom there was evidence that they should receive chemotherapy at least once.
Materials And Methods:
An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy identified from evidence-based treatment guidelines. Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate an optimal chemotherapy utilisation rate. This optimal rate was compared with reported actual rates of chemotherapy utilisation.
Results:
Chemotherapy is indicated at least once, either as an initial treatment or at recurrence (in those who have not previously received chemotherapy), in 72% of all patients with primary malignant brain tumours. No recent published data on actual chemotherapy utilisation rates were identified for comparison with the optimal rate.
Conclusion:
The optimal chemotherapy utilisation rate can serve as an evidence-based benchmark in the planning and evaluation of chemotherapy services for brain cancer. There are no recent published patterns of care studies that report on chemotherapy utilisation rates for primary malignant brain tumours; future research should focus on filling this gap.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...